Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Recruiting · NCT05017311 · Interventional (participants receive a specific treatment) · Lead sponsor: Nova Scotia Health Authority
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is a study that will test a predictive biomarker algorithm based on results from a previous study. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Outpatients 18 to 65 years of age.
- Meet DSM-5 criteria for MDE in MDD as determined by SCID-5.
- Free of psychotropic medications for at least 5 half-lives (e.g. 1 week for most antidepressants, 5 weeks for fluoxetine) before baseline Visit 1 (exceptions: stable use of hypnotics; stable use of stimulants for attention-deficit/hyperactive disorder).
- MADRS score ≥ 24.
- Fluency in English, sufficient to complete the interviews and self-report questionnaires.
Exclusion criteria
- Any diagnosis, other than MDD, that is considered the primary diagnosis.
- Bipolar I or Bipolar-II diagnosis.
- Presence of a significant Axis II diagnosis (borderline, antisocial).
- High suicidal risk, defined by clinician judgment.
- Substance dependence/abuse in the past 6 months.
- Presence of significant neurological disorders, head trauma, or other unstable medical conditions.
- Pregnant or breastfeeding.
- Failure of 4 or more adequate pharmacologic interventions (as determined by the Antidepressant Treatment History Form).
- Started psychological treatment within the past 3 months with the intent of continuing treatment.
- Patients who have previously failed escitalopram or showed intolerance to escitalopram or brexpiprazole, and patients at risk for hypomanic switch (i.e. with a history of antidepressant induced hypomania).
- Healthy Comparison (HC) Participants
- Inclusion Criteria:
- 18 to 65 years of age.
- No history of psychiatric disorders (as determined by SCID-5) or significant physical conditions (e.g. arthritis, fibromyalgia).
- Fluency in English, sufficient to complete the interviews and self-report questionnaires.
Where it is running
10 locations listed.
- University of Calgary - Calgary, Alberta, Canada
- University of British Columbia - Vancouver, British Columbia, Canada
- Nova Scotia Health Authority - Halifax, Nova Scotia, Canada
- McMaster University - Hamilton, Ontario, Canada
- Queen's University - Kingston, Ontario, Canada
- The Royal Ottawa Mental Health Centre - Ottawa, Ontario, Canada
- University Health Network - Toronto, Ontario, Canada
- Centre for Addiction and Mental Health - Toronto, Ontario, Canada
- Ontario Shores Centre for Mental Health Sciences - Whitby, Ontario, Canada
- University of Saskatchewan - Saskatoon, Saskatchewan, Canada